Compare medicines
Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.
| Attribute | ||
|---|---|---|
| In short | Targeted pill that turned a deadly leukaemia into a manageable condition. | Targeted pill for EGFR-mutated lung cancer. |
| Body system | Cancer | Cancer |
| Drug class | Tyrosine kinase inhibitors | Tyrosine kinase inhibitors |
| Supply | Prescription onlyWHO essential medicine | Prescription only |
| Main uses | Chronic myeloid leukaemia, Philadelphia-positive ALL, Gastrointestinal stromal tumour (GIST) | EGFR-mutated non-small cell lung cancer (advanced and after surgery) |
| How it works | Switches off the faulty protein that makes leukaemia cells grow. | Blocks a faulty growth switch in some lung cancers. |
| Starts working | — | — |
| Half-life | About 18 hours | About 48 hours |
| Typical adult dose | Usually 400 mg once a day with food. | 80 mg once a day. |
| Forms | Tablet | Tablet |
| Common side effects | Swelling around the eyes, Muscle cramps, Nausea, Diarrhoea, Rash | Diarrhoea, Rash, Dry skin, Nail infections |
| Serious side effects | Fluid retention, Low blood counts, Liver injury, Heart failure (rare) | Lung inflammation, QT prolongation, Heart failure |
| Don't take if | — | — |
| Alcohol | — | — |
| Pregnancy | Usually avoidedEffective contraception needed. | Usually avoidedContraception needed. |
| Breastfeeding | — | — |
| In use since | 2001 | 2015 |
| Brand names | United States: GleevecUnited Kingdom: GlivecIndia: Veenat, Imatib | United States: TagrissoUnited Kingdom: TagrissoIndia: Tagrisso |
| Legal status | — | — |
| ATC code | L01EA01 | L01EB04 |
Taken together
No interaction between these medicines is recorded in the atlas.
Open in the interaction checker